Trius Therapeutics (TSRX) announced it has been awarded a research contract by Lawrence Livermore National Laboratory, part of the DOE's National Nuclear Security Administration, for the development of novel antibiotics directed against multi-drug resistant bacterial pathogens. Co may receive up to $3.0 mln over three years in support of its development efforts.